United Kingdom-Redcar: Pharmaceutical products
Get tender notifications and more sign up now and never miss an opportunity again. Already a member? log in to your account.
| Title | United Kingdom-Redcar: Pharmaceutical products |
| OJEU (High Value) | 305190-2020 |
| Type | Invitation to tender |
| Date Published | 2020-06-30 |
| Deadline | 2020-07-10 12:00:00 |
| Nature Of Contract | Supply contract |
| Awarding Authority | |
| Procedure | Open procedure |
| Description : |
|
I.1) Name and addresses: NUTS code: UKC Communication I.3) Procurement documents (URL):https://ne1procurementservices.com/ Additional Information I.3.4) Additional information can be obtained from: I.3.8) to the above mentioned address I.4) Type of the contracting authority: BODY PUBLIC I.5.2) Other activity - Technology development Framework for the Ongoing Supply of Plasmid II.1.4) Short description In response to the Covid-19 vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. This tender is split into 3 lots: 1) to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli; 2) from the MCB, supply 10g of purified linearised plasmid manufactured according to GMP. (to simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder); 3) provision of the combined services of lot 1 and 2. II.01) Estimated value excluding VAT: GBP 10000000.00 II.1.6) This contract is divided into lots: yes Generation and Validation of a Master Cell Bank for Plasmid Production II.2.1) Lot No: 1 NUTS code: UKC II.1.4) Short description In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. II.2.5) Award criteria: II.02.07) Duration in months 24 II.2.7.5) This contract is subject to renewal: yes II.2.7.6) Description of renewals: CPI have the option to extend by 2 x 12-month periods. II.2.10) Variants will be accepted: no The procurement is related to a project and/or programme financed by European Union funds): no Supply 10g of Purified Linearised Plasmid II.2.1) Lot No: 2 NUTS code: UKC II.1.4) Short description In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to supply 10 g of purified linearised plasmid manufactured according to GMP. II.2.5) Award criteria: II.02.07) Duration in months 24 II.2.7.5) This contract is subject to renewal: yes II.2.7.6) Description of renewals: CPI have the option to extend by 2 x 12-month periods. II.2.10) Variants will be accepted: no The procurement is related to a project and/or programme financed by European Union funds): no Supply 10 g of Purified Linearised Plasmid II.2.1) Lot No: 3 NUTS code: UKC II.1.4) Short description In response to the Covid-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. From the MCB, they are expecited supply 10 g of purified linearised plasmid manufactured according to GMP. (To simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder). II.2.5) Award criteria: II.02.07) Duration in months 24 II.2.7.5) This contract is subject to renewal: yes II.2.7.6) Description of renewals: CPI have the option to extend by 2 x 12-month periods. II.2.10) Variants will be accepted: no The procurement is related to a project and/or programme financed by European Union funds): no III.1.2) Economic and financial standing III.1.2.2) Selection criteria as stated in the procurement documents III.1.3) Technical and professional ability III.1.3.1.2) Selection criteria as stated in the procurement documents IV.1.1) Type of procedure: Open IV.1.1)Accelerated procedure IV.1.1.2) Justification The Covid-19 outbreak has given rise to an urgent need for the Plasmid for CPI as it is required in response for the urgent need to develop a vaccine. This does not give CPI sufficient time to comply with the standard open procedure timescales for this procurement. CPI considers this to be a state of urgency which it has duly substantiated. Accordingly, CPI is using the accelerated time limits permitted under the Public Contract Regulations 2015 (regulation [27(5) for the open procedure) in respect of this procurement. IV.1.3) The procurement involves the establishment of a framework agreement IV.1.3) Envisaged maximum number of participants to the framework agreement 2 IV.2.1) Time limit for receipt of tenders or requests to participate IV.2.2) Date 2020-07-10 IV.2.2) Local time 12:00 IV.2.7) Conditions for opening of tenders IV.2.7) Date 2020-07-10 IV.2.7) Local time 12:01 Review body: Date of dispatch of this notice : 2020-06-25 |
| CPV Codes |
| 33600000; Pharmaceutical products; |
Sign-up now to receive weekly OJEU reports for the UK, your sector and/or elsewhere in the EU. We also report on the procurement of EC Institutions. |
|